Gilman Hill Asset Management LLC Grows Stock Position in Eli Lilly and Company (NYSE:LLY)

Gilman Hill Asset Management LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 46.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,136 shares of the company’s stock after acquiring an additional 1,940 shares during the quarter. Gilman Hill Asset Management LLC’s holdings in Eli Lilly and were worth $1,989,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. McLean Asset Management Corp boosted its stake in Eli Lilly and by 2.4% in the 1st quarter. McLean Asset Management Corp now owns 1,405 shares of the company’s stock worth $402,000 after purchasing an additional 33 shares during the period. RB Capital Management LLC boosted its stake in Eli Lilly and by 1.4% in the 2nd quarter. RB Capital Management LLC now owns 2,382 shares of the company’s stock worth $772,000 after purchasing an additional 33 shares during the period. Woodstock Corp boosted its stake in Eli Lilly and by 0.6% in the 2nd quarter. Woodstock Corp now owns 5,585 shares of the company’s stock worth $1,811,000 after purchasing an additional 34 shares during the period. Affiance Financial LLC boosted its position in shares of Eli Lilly and by 1.9% during the 1st quarter. Affiance Financial LLC now owns 1,835 shares of the company’s stock valued at $525,000 after acquiring an additional 35 shares during the last quarter. Finally, Ashfield Capital Partners LLC boosted its position in shares of Eli Lilly and by 0.5% during the 1st quarter. Ashfield Capital Partners LLC now owns 7,975 shares of the company’s stock valued at $2,284,000 after acquiring an additional 36 shares during the last quarter. 82.45% of the stock is currently owned by institutional investors.

Eli Lilly and Stock Up 0.9 %

NYSE LLY traded up $2.92 during trading on Friday, hitting $313.79. The company’s stock had a trading volume of 68,247 shares, compared to its average volume of 2,237,822. Eli Lilly and Company has a fifty-two week low of $220.20 and a fifty-two week high of $335.33. The company has a market cap of $298.15 billion, a PE ratio of 49.58, a P/E/G ratio of 1.92 and a beta of 0.38. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.10 and a quick ratio of 0.85. The business’s 50 day simple moving average is $314.33 and its 200-day simple moving average is $304.45.

Eli Lilly and (NYSE:LLYGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). The company had revenue of $6.49 billion for the quarter, compared to analysts’ expectations of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.87 earnings per share. On average, equities analysts anticipate that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 9th. Stockholders of record on Monday, August 15th were given a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date of this dividend was Friday, August 12th. Eli Lilly and’s dividend payout ratio (DPR) is presently 62.52%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LLY. Barclays increased their target price on Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a research report on Thursday, July 7th. StockNews.com upgraded Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 14th. JPMorgan Chase & Co. increased their target price on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Morgan Stanley increased their target price on Eli Lilly and from $395.00 to $412.00 and gave the company an “overweight” rating in a research report on Wednesday, September 7th. Finally, Citigroup increased their price target on Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $332.19.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 177,243 shares of the business’s stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $330.28, for a total value of $58,539,818.04. Following the completion of the sale, the insider now directly owns 103,983,810 shares in the company, valued at $34,343,772,766.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Lilly Endowment Inc sold 177,243 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $330.28, for a total value of $58,539,818.04. Following the sale, the insider now directly owns 103,983,810 shares of the company’s stock, valued at $34,343,772,766.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jackson P. Tai purchased 656 shares of the stock in a transaction dated Friday, August 12th. The stock was purchased at an average cost of $304.19 per share, for a total transaction of $199,548.64. Following the completion of the purchase, the director now directly owns 62,857 shares of the company’s stock, valued at $19,120,470.83. The disclosure for this purchase can be found here. Insiders sold 328,125 shares of company stock worth $108,581,151 over the last three months. 0.12% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.